{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:13:53Z","timestamp":1788779633670,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-05078-y","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:57:08Z","timestamp":1782215828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and factors associated with chemotherapy induced peripheral neuropathy among adult patients with cancer at Mbarara Regional Cancer Centre: a cross-sectional study"],"prefix":"10.1186","volume":"26","author":[{"given":"Stanslas","family":"Avaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Ndrusini","family":"Ngbape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdu","family":"Damale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idrine Kalinge","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bacia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nakate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Kyomya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Isiiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tamukong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadele Mekuriya","family":"Yadesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"4","key":"5078_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.31662\/jmaj.2021-0015","volume":"5","author":"R Tamang","year":"2022","unstructured":"Tamang R, Bharati L, Khatiwada AP, Ozaki A, Shrestha S. Pattern of adverse drug reactions associated with the use of anticancer drugs in an oncology-based hospital of Nepal. JMA J. 2022;5(4):416\u201326.","journal-title":"JMA J"},{"issue":"3","key":"5078_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"key":"5078_CR3","unstructured":"GLOBOCAN. International Agency for Research on Cancer (IARC)-WHO. 2024. Available from: https:\/\/gco.iarc.who.int\/today."},{"issue":"3","key":"5078_CR4","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/cancers3033279","volume":"3","author":"M Arruebo","year":"2011","unstructured":"Arruebo M, Vilaboa N, S\u00e1ez-Gutierrez B, Lambea J, Tres A, Valladares M, et al. Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 2011;3(3):3279\u2013330.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"5078_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.9734\/jpri\/2020\/v32i1130499","volume":"32","author":"M Singaraju","year":"2020","unstructured":"Singaraju M, Palaian S, Shankar PR, Shrestha S. Safety profile and toxicity amelioration strategies of common adverse effects associated with anticancer medications. J Pharm Res Int. 2020;32(11):18\u201330.","journal-title":"J Pharm Res Int"},{"issue":"6","key":"5078_CR6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.breast.2008.05.006","volume":"17","author":"S-H Kuo","year":"2008","unstructured":"Kuo S-H, Lien H-C, You S-L, Lu Y-S, Lin C-H, Chen T-Z, et al. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I\u2013II and operable stage III Taiwanese breast cancer patients. Breast. 2008;17(6):646\u201353.","journal-title":"Breast"},{"issue":"6","key":"5078_CR7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","volume":"20","author":"R Zaj\u0105czkowska","year":"2019","unstructured":"Zaj\u0105czkowska R, Kocot-K\u0119pska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451.","journal-title":"Int J Mol Sci"},{"key":"5078_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","volume":"10","author":"H Starobova","year":"2017","unstructured":"Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174.","journal-title":"Front Mol Neurosci"},{"issue":"12","key":"5078_CR9","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain\u00ae. 2014;155(12):2461\u201370.","journal-title":"Pain\u00ae"},{"issue":"12","key":"5078_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nrneurol.2010.160","volume":"6","author":"G Cavaletti","year":"2010","unstructured":"Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Reviews Neurol. 2010;6(12):657\u201366.","journal-title":"Nat Reviews Neurol"},{"issue":"7","key":"5078_CR11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1001\/jamaneurol.2016.0383","volume":"73","author":"NA Kolb","year":"2016","unstructured":"Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 2016;73(7):860\u20136.","journal-title":"JAMA Neurol"},{"issue":"6","key":"5078_CR12","first-page":"571","volume":"21","author":"S Hou","year":"2018","unstructured":"Hou S, Huh B, Kim HK, Kim K-H, Abdi S. Treatment of chemotherapy-induced peripheral neuropathy: systematic review and recommendations. Pain Physician. 2018;21(6):571.","journal-title":"Pain Physician"},{"issue":"6","key":"5078_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"NP Staff","year":"2017","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772\u201381.","journal-title":"Ann Neurol"},{"issue":"4","key":"5078_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/bja\/aex229","volume":"119","author":"S Flatters","year":"2017","unstructured":"Flatters S, Dougherty P, Colvin L. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review. BJA: Br J Anaesth. 2017;119(4):737\u201349.","journal-title":"BJA: Br J Anaesth"},{"key":"5078_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2016.09.020","volume":"69","author":"F Mols","year":"2016","unstructured":"Mols F, van de Poll-Franse LV, Vreugdenhil G, Beijers AJ, Kieffer JM, Aaronson NK, et al. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 questionnaire in the general Dutch population. Eur J Cancer. 2016;69:28\u201338.","journal-title":"Eur J Cancer"},{"key":"5078_CR16","doi-asserted-by":"publisher","first-page":"637593","DOI":"10.3389\/fphar.2021.637593","volume":"12","author":"M Selvy","year":"2021","unstructured":"Selvy M, Kerckhove N, Pereira B, Barreau F, Nguyen D, Busserolles J, et al. Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: a single center cross-sectional study. Front Pharmacol. 2021;12:637593.","journal-title":"Front Pharmacol"},{"issue":"14","key":"5078_CR17","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/(SICI)1097-0258(19980730)17:14<1551::AID-SIM868>3.0.CO;2-E","volume":"17","author":"LD Fisher","year":"1998","unstructured":"Fisher LD. Self-designing clinical trials. Stat Med. 1998;17(14):1551\u201362.","journal-title":"Stat Med"},{"key":"5078_CR18","first-page":"1","volume":"5","author":"MS Ezzi","year":"2019","unstructured":"Ezzi MS, Othieno-Abinya NA, Amayo E, Oyiro P, McLigeyo A, Yatich RB, et al. Prevalence and predictors of cisplatin-induced peripheral neuropathy at the Kenyatta National Hospital. J global Oncol. 2019;5:1\u20136.","journal-title":"J global Oncol"},{"issue":"8","key":"5078_CR19","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","volume":"41","author":"TJ Postma","year":"2005","unstructured":"Postma TJ, Aaronson N, Heimans J, Muller M, Hildebrand J, Delattre J-Y, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005;41(8):1135\u20139.","journal-title":"Eur J Cancer"},{"issue":"2","key":"5078_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"5078_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/0284186X.2021.2007283","volume":"61","author":"SW Nielsen","year":"2022","unstructured":"Nielsen SW, Eckhoff L, Ruhlmann CHB, Herrstedt J, Dalton SO. The prevalence, distribution and impact of peripheral neuropathy among Danish patients with cancer\u2013a population-based cross-sectional study. Acta Oncol. 2022;61(3):363\u201370.","journal-title":"Acta Oncol"},{"issue":"9","key":"5078_CR22","first-page":"2229","volume":"49","author":"SC Hartwig","year":"1992","unstructured":"Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229\u201332.","journal-title":"Am J Hosp Pharm"},{"key":"5078_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","volume":"159","author":"T Bao","year":"2016","unstructured":"Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159:327\u201333.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"5078_CR24","doi-asserted-by":"publisher","first-page":"e01312","DOI":"10.1002\/brb3.1312","volume":"9","author":"A Molassiotis","year":"2019","unstructured":"Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane\u2010and platinum\u2010based chemotherapy. Brain Behav. 2019;9(6):e01312.","journal-title":"Brain Behav"},{"key":"5078_CR25","doi-asserted-by":"crossref","unstructured":"Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L et al. Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology\/NSABP B-30. JNCI: Journal of the National Cancer Institute. 2018;110(2):djx162.","DOI":"10.1093\/jnci\/djx162"},{"issue":"2","key":"5078_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jpainsymman.2016.12.342","volume":"54","author":"C Miaskowski","year":"2017","unstructured":"Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B, Abrams G, et al. Chemotherapy-induced neuropathy in cancer survivors. J Pain Symptom Manag. 2017;54(2):204\u201318. e2.","journal-title":"J Pain Symptom Manag"},{"key":"5078_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00520-005-0868-6","volume":"14","author":"AA Argyriou","year":"2006","unstructured":"Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Gourzis P, Assimakopoulos K, et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer. 2006;14:223\u20139.","journal-title":"Support Care Cancer"},{"issue":"6","key":"5078_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","volume":"63","author":"SB Park","year":"2013","unstructured":"Park SB, Goldstein D, Krishnan AV, Lin CSY, Friedlander ML, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. Cancer J Clin. 2013;63(6):419\u201337.","journal-title":"Cancer J Clin"},{"key":"5078_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-014-1632-x","volume":"121","author":"JLM Jongen","year":"2015","unstructured":"Jongen JLM, Broijl A, Sonneveld P. Chemotherapy-induced peripheral neuropathies in hematological malignancies. J Neurooncol. 2015;121:229\u201337.","journal-title":"J Neurooncol"},{"issue":"1","key":"5078_CR30","first-page":"38","volume":"15","author":"MR Jones","year":"2020","unstructured":"Jones MR, Urits I, Wolf J, Corrigan D, Colburn L, Peterson E, et al. Drug-induced peripheral neuropathy: a narrative review. Curr Clin Pharmacol. 2020;15(1):38\u201348.","journal-title":"Curr Clin Pharmacol"},{"issue":"5","key":"5078_CR31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3109\/0284186X.2014.995775","volume":"54","author":"M Ewertz","year":"2015","unstructured":"Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol. 2015;54(5):587\u201391.","journal-title":"Acta Oncol"},{"issue":"13","key":"5078_CR32","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EML Smith","year":"2013","unstructured":"Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359\u201367.","journal-title":"JAMA"},{"issue":"9","key":"5078_CR33","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/cncr.23008","volume":"110","author":"RD Rao","year":"2007","unstructured":"Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double\u2010blind, placebo\u2010controlled, crossover trial (N00C3). Cancer. 2007;110(9):2110\u20138.","journal-title":"Cancer"},{"issue":"1","key":"5078_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jpainsymman.2007.02.043","volume":"35","author":"A-L Kautio","year":"2008","unstructured":"Kautio A-L, Haanp\u00e4\u00e4 M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manag. 2008;35(1):31\u20139.","journal-title":"J Pain Symptom Manag"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05078-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05078-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05078-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:03:54Z","timestamp":1788779034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05078-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5078"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05078-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Mbarara University of Science and Technology Research Ethics Committee (MUST REC) with reference number MUST-2024-1484. Additionally, administrative clearance was provided by the hospital director of MRRH before the study commenced. Informed consent was sought from patients who fulfilled the criteria for inclusion before they were enrolled into the study. The informed consent form was translated into Runyankole, the local language, to assist participants who had limited literacy skills. For those who couldn\u2019t read, the translated form was read aloud, and participants expressed their consent by using their thumbprints. To enhance the integrity of the process, literate family members or caregivers served as witnesses, ensuring that the content was accurately conveyed and confirmed to the participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"564"}}